CLINICAL TRIALS PROFILE FOR MOVIPREP

All Clinical Trials for MOVIPREP

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00312481 ↗	MOVIPREP® Versus PICOLAX® Pilot Study	Completed	Norgine	Phase 2	2005-07-01	This will be a randomised, single-centre, single-blind, parallel-group, pilot study in patients undergoing colonoscopy. The primary objective is to evaluate the efficacy of MOVIPREP® versus PICOLAX® for gut cleansing prior to colonoscopy. The secondary objectives are to evaluate the safety, tolerability and acceptability of MOVIPREP versus PICOLAX for gut cleansing prior to colonoscopy.
NCT00322062 ↗	MOVIPREP® Versus NaP Pivotal Phase III Study	Completed	Norgine	Phase 3	2002-04-01	The aim of the study is to compare a new 2 litre bowel cleansing product versus a sodium phosphate solution already on the market. Efficacy of each bowel preparation, safety and acceptability will be assessed.
NCT00389233 ↗	A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution	Completed	Norgine	Phase 3	2002-06-01	The study was carried out as a randomised, single-blind, active-controlled, multi-centric, phase III study with two parallel treatment groups. The primary efficacy criterion was the frequency of effective gut cleansing in each of the two treatment groups (grade A or B "overall quality of gut cleansing" as judged by a blinded expert panel on the basis of videotapes recorded during the endoscopic procedure).
NCT00427089 ↗	Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening	Completed	Norgine	Phase 3	2004-09-01	To compare the efficacy, acceptability and safety of the new 2 liter gut cleansing solution (Moviprep) and NaP preparation in routine colon cleansing prior to tumor screening colonoscopies
NCT00605228 ↗	A Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation	Completed	International Clinical Trials Association	Phase 4	2007-05-01	Primary: - To demonstrate the superiority of Moviprep® versus Colopeg® in gut cleansing prior to colonoscopy. Secondary: - To assess the safety of Moviprep® versus Colopeg®. - To assess acceptability of Moviprep® versus Colopeg®.
NCT00605228 ↗	A Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation	Completed	Norgine	Phase 4	2007-05-01	Primary: - To demonstrate the superiority of Moviprep® versus Colopeg® in gut cleansing prior to colonoscopy. Secondary: - To assess the safety of Moviprep® versus Colopeg®. - To assess acceptability of Moviprep® versus Colopeg®.

Clinical Trial Conditions for MOVIPREP

Condition Name

Condition Name for MOVIPREP
Intervention	Trials
Colonoscopy	8
Colorectal Cancer	5
Colon Disease	3
Colon Cancer	2

Condition MeSH

Condition MeSH for MOVIPREP
Intervention	Trials
Colorectal Neoplasms	4
Colonic Diseases	3
Colonic Neoplasms	3
Gastrointestinal Diseases	2

Clinical Trial Locations for MOVIPREP

Trials by Country

Trials by Country for MOVIPREP
Location	Trials
Italy	20
United States	18
Germany	13
United Kingdom	6
France	5

Trials by US State

Trials by US State for MOVIPREP
Location	Trials
Indiana	2
Arizona	2
Illinois	2
Pennsylvania	2
Ohio	1

Clinical Trial Progress for MOVIPREP

Clinical Trial Phase

Clinical Trial Phase for MOVIPREP
Clinical Trial Phase	Trials
Phase 4	11
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MOVIPREP
Clinical Trial Phase	Trials
Completed	26
Not yet recruiting	5
Unknown status	4

Clinical Trial Sponsors for MOVIPREP

Sponsor Name

Sponsor Name for MOVIPREP
Sponsor	Trials
Norgine	13
University of Nottingham	2
Gastroenterology Services, Ltd.	2

Sponsor Type

Sponsor Type for MOVIPREP
Sponsor	Trials
Other	35
Industry	24

Moviprep: Clinical Trial Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is Moviprep?

Moviprep is an oral bowel-cleansing solution containing macrogol (polyethylene glycol) 3350, combined with electrolytes, used for colonoscopy preparation. Its primary purpose is to cleanse the bowel to enable accurate visualization during endoscopy.

Clinical Trial Status and Updates

Current Clinical Trial Landscape

As of 2023, Moviprep has completed multiple clinical trials focused on safety, efficacy, and patient tolerability. The key recent studies include:

• Efficacy Comparison: Trials comparing Moviprep to other bowel preparations, such as GoLYTELY and MiraLAX-based solutions, consistently demonstrating comparable colon cleansing quality.
• Patient Tolerability: Studies show Moviprep has similar or better tolerability, with fewer reports of nausea, bloating, or abdominal discomfort.
• Safety Profile: No significant adverse events reported across large sample sizes (n > 500 in recent trials).

Regulatory Approvals and Changes

• FDA: Approved in the U.S. since 2003 under the indication for bowel cleansing before colonoscopy.
• EMA: Approved in Europe, with variations in recommended usage.
• Recent updates include adjustments to dosage instructions to improve patient compliance and safety, particularly regarding electrolyte balance in vulnerable populations.

Ongoing and Planned Trials

Currently, limited new clinical trials are underway, mainly focusing on:

• Use in specific patient populations, including pediatric and elderly: no major new trials announced recently.
• Comparative studies with emerging low-volume preparations: minimal activity reported.

Market Analysis

Market Size and Growth

The global bowel preparation market was valued at approximately USD 1.5 billion in 2022 and is projected to reach USD 2.3 billion by 2027, exhibiting a CAGR of 9.2%. Moviprep accounts for an estimated 20% market share, positioning it as a leading brand.

Key Market Segments

• By Geography:

  • North America: Largest market due to high colonoscopy volume; estimates 60% of global sales.
  • Europe: Growing adoption, supported by guideline updates and availability.
  • Asia-Pacific: Rapid growth driven by increased screening programs and awareness.

• By Patient Demographics:

  • Adults aged 50–75 years are the primary users.
  • Use in low-risk populations is routine; high-risk groups, such as elderly or comorbid patients, show increased preference due to safety profile.

Competitive Landscape

Main competitors include:

• GoLYTELY (Braintree Laboratories): Established brand, high volume usage.
• MiraLAX (Baxter Healthcare): Popular due to over-the-counter availability.
• NuLYTELY (Braintree): Similar formulation with distinct branding.
• Low-volume preparations such as NER1006 and Picoprep entering niche markets.

Market strategies focus on improving palatability, reducing prep volume, and enhancing safety.

Pricing and Reimbursement

• Pricing: Generally ranges from USD 20 to USD 60 per regimen, depending on region and formulation.
• Reimbursement policies: Favorable in the U.S., with coverage by major insurance providers, encouraging widespread adoption.

Future Market Projections

Drivers of Growth

• Increase in colorectal cancer screening rates, especially in aging populations.
• Growing awareness of bowel health.
• Advances leading to low-volume and more tolerable preparations.

Challenges and Risks

• Competition from newer, lower-volume formulations.
• Regulatory hurdles for specific populations.
• Patient compliance issues linked to taste and volume.

Strategic Opportunities

• Expansion into emerging markets.
• Marketing tailored to elderly and pediatric patients.
• Development of combination preparations with faster action and improved taste.

Key Takeaways

• Moviprep has a stable clinical profile, with ongoing confirmation of safety and efficacy.
• The bowel preparation market is growing driven by aging populations and increased screening.
• Moviprep holds a significant market share, but faces competition from low-volume and innovative formulations.
• Future growth depends on geographic expansion, formulation improvements, and patient-centered marketing.

FAQs

1. What recent clinical trial data support Moviprep’s safety?
Large trials show no significant adverse effects, with consistent safety profiles across diverse populations.

2. How does Moviprep compare to low-volume bowel preparations?
It has similar efficacy but often requires larger volumes; newer low-volume options aim to improve tolerability.

3. What regions are driving growth in Moviprep’s sales?
North America and Europe lead due to high screening rates; Asia-Pacific shows rapid market expansion.

4. Are there any contraindications for Moviprep?
Yes; contraindicated in patients with bowel blockage, perforation, or severe electrolyte disturbances.

5. What are the outlook and opportunities for Moviprep?
Market stability with growth prospects from emerging markets and formulation advancements focusing on patient comfort.

---

References

[1] MarketWatch. (2023). Bowel Preparation Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2003). Approval documentation for Moviprep.
[3] European Medicines Agency. (2022). Moviprep product information summary.
[4] Grand View Research. (2023). Colonoscopy & Bowel Prep Market Size, Share & Trends.